Johnson & Johnson Buys Spine Tech, Gets FDA Nod for Heart Device

Johnson & Johnson (NYSE:JNJ) has announced two major developments in its MedTech division: the acquisition of Expanding Innovations by its DePuy Synthes unit, and FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform for cardiac ablation.

Acquisition Details

DePuy Synthes, part of Johnson & Johnson MedTech, acquired Expanding Innovations, a company specializing in expandable interbody technologies for spine surgery. The financial terms of the deal were not disclosed.

FDA Approval

The FDA approved the Dual Energy THERMOCOOL SMARTTOUCH SF Platform, an advanced ablation system for treating atrial fibrillation and other arrhythmias. The platform adds dual-energy capabilities to Johnson & Johnson's existing electrophysiology portfolio.

Context

These moves come as JNJ stock trades at $253.04, with a value_score of 2 according to Simply Wall St. The developments underscore Johnson & Johnson's commitment to expanding its MedTech offerings.

What This Means for Investors

The acquisition and FDA approval expand Johnson & Johnson's presence in spine surgery and cardiac ablation. While they could drive future revenue growth, the full impact will depend on successful commercialization.